Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 12, 2011, Pages 3245-3249

  Cao, Xiao Lin ^a   Xu, Ru Jun ^a   Zheng, You Yang ^b   Liu, Jun ^c   Teng, Yao Shu ^a   Li, Yong ^a   Zhu, Jin ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Collagen; Laryngeal scc; Metalloproteinase; Tissue inhibitor of metalloproteinase

Indexed keywords

COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; MMP2 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; LARYNX; LARYNX TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COLLAGEN TYPE IV; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; LARYNX; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84864509603     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Aref S, Osman E, Mansy S, et al (2007). Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol Oncol, 25, 121-6.
2. Courey MS, Shohet JA, Scott MA, Ossoff RH (1996). Immunohistochemical characterization of benign laryngeal lesions. Ann Otol Rhinol Laryngol, 105, 525-31.
3. Dong W, Li H, Zhang Y, et al (2011). Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai). 2011 Oct 3.
4. Franchi A, Santucci M, Masini E, et al (2002). Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer, 95, 1902-10.
5. Figueira RC, Gomes LR, Neto JS, et al (2009). Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer, 9, 20.
6. Gandini S, Botteri E, Iodice S, et al (2008). Tobacco smoking and cancer: a meta-analysis. Int J Cancer, 122, 155-64.
7. Gomez DE, Alonso DF, Yoshiji H (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol, 74, 111-5.
8. Islami F, Tramacere I, Rota M, et al (2010). Alcohol drinking and laryngeal cancer: overall and dose-risk relation-a systematic review and meta-analysis. Oral Oncol, 46, 802-10.
9. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES (2004). The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol, 50, 87-100.
10. Kondratiev S, Gnepp DR, Yakirevich E, et al (2008). Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Hum Pathol, 39, 337-43.
11. Krecicki T, Fraczek M, Jelen M, et al (2003). Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol, 260, 494-7.
12. Krecicki T, Zalesska-Krecicka M, Jelen M, et al (2001). Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in laryngeal cancer. Clin Otolaryngol, 26, 469-72.
13. Kugler A, Hemmerlein B, Thelen P, et al (1988). Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol, 160, 1914-8.
14. Leblond CP, Inoue S (1989). Structure, composition and assembly of basement membrane. Am J Anat, 185, 367-90.
15. Liotta LA, Rao CN, Barsky SH (1983). Tumor invasion and the extracellular matrix. Lab Invest, 49, 636-49.
16. Maestro R, Dolcetti R, Gasparotto D, et al (1992). High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 7, 1159-66.
17. Martins RH, Defaveri J, Custódio Domingues MA, et al (2010). Vocal fold nodules: morphological and immunohistochemical investigations. J Voice, 24, 531-9.
18. Marur S, D'Souza G, Westra WH, Forastiere AA (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol, 11, 781-9.
19. Molica S, Vitelli G, Levato D, et al (2003). Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. EurJ Haematol, 70, 373-8.
20. Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002). Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int, 52, 255-64.
21. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000). Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18, 1135-49.
22. Overall CM, López-Otín C (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer, 2, 657-72.
23. Peschos D, Damala C, Stefanou D, et al (2006). Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol, 21, 603-8.
24. Rosenthal EL, Johnson TM, Allen ED, et al (1998). Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res, 58, 5221-30.
25. Shi Y, Parhar RS, Zou M, et al (1999). Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma. Br J Cancer, 79, 1234-9.
26. Suminoe A, Matsuzaki A, Hattori H, et al (2007). Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res, 31, 1437-40.
27. Travaglino E, Benatti C, Malcovati L, et al (2008). Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. EurJ Haematol, 80, 216-26.
28. Trudel D, Fradet Y, Meyer F, Têtu B (2010). Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Hum Pathol, 41, 1694-701.
29. Wang Y, Sun WY, Guan C, et al (2011). Distribution of basement membrane in supraglottic carcinoma. Pathol Oncol Res, 17, 1-5.
30. Wittekindt C, Jovanovic N, Guntinas-Lichius O (2011). Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol, 131, 101-6.
31. Woessner JF Jr (1994). The family of matrix metalloproteinases. Ann N Y Acad Sci, 732, 11-21.
32. Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005). Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50.